[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::43475268.png) @bio_clouseau M

M posts on X about $gsk, $eidx, $bbio, $tsro the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::43475268/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::43475268/c:line/m:interactions.svg)

- X Week XXXXXX +242%
- X Month XXXXXX -XX%
- X Months XXXXXXX +27%
- X Year XXXXXXXXX +48%

### Mentions: XX [#](/creator/twitter::43475268/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::43475268/c:line/m:posts_active.svg)

- X Week XX +20%
- X Month XX -XX%
- X Months XXX +6.70%
- X Year XXX +217%

### Followers: XXXXXX [#](/creator/twitter::43475268/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::43475268/c:line/m:followers.svg)

- X Week XXXXXX +0.27%
- X Month XXXXXX +0.54%
- X Months XXXXXX +2%
- X Year XXXXXX +5%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::43475268/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::43475268/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::43475268/influence)
---

**Social category influence**
[stocks](/list/stocks)  XXXX% [finance](/list/finance)  XXXX% [currencies](/list/currencies)  XXXX% [cryptocurrencies](/list/cryptocurrencies)  XXXX%

**Social topic influence**
[$gsk](/topic/$gsk) 6.94%, [$eidx](/topic/$eidx) 5.56%, [$bbio](/topic/$bbio) 5.56%, [$tsro](/topic/$tsro) 4.17%, [$ecyt](/topic/$ecyt) 2.78%, [$nvs](/topic/$nvs) 2.78%, [$mrk](/topic/$mrk) 2.78%, [compound](/topic/compound) 2.78%, [has been](/topic/has-been) 2.78%, [$clvs](/topic/$clvs) XXXX%

**Top accounts mentioned or mentioned by**
[@jq1234t](/creator/undefined) [@jacobplieth](/creator/undefined) [@bertrandbio](/creator/undefined) [@sanctuarybio](/creator/undefined) [@sirtsix](/creator/undefined) [@nolastevedore](/creator/undefined) [@byamybrown](/creator/undefined) [@bymadeleinea](/creator/undefined) [@syinvesting](/creator/undefined) [@gcbioinv](/creator/undefined) [@evaluatevantage](/creator/undefined) [@applehelix](/creator/undefined) [@pilldipp](/creator/undefined) [@chiragontwtr](/creator/undefined) [@dogehippie](/creator/undefined) [@avidresearch](/creator/undefined) [@sanctuary_bio](/creator/undefined) [@ndrewcolburn](/creator/undefined) [@davidc85097716](/creator/undefined) [@joserestonva](/creator/undefined)

**Top assets mentioned**
[GSK plc (GSK)](/topic/$gsk) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [Novartis AG (NVS)](/topic/$nvs) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Summit Therapeutics Inc. Common Stock (SMMT)](/topic/$smmt) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Prothena Corporation plc Ordinary Shares (PRTA)](/topic/$prta) [IVERIC bio, Inc. Common Stock (ISEE)](/topic/$isee) [Apellis Pharmaceuticals, Inc. Common Stock (APLS)](/topic/$apls) [Mirati Therapeutics, Inc. Common Stock (MRTX)](/topic/$mrtx) [Amgen, Inc. (AMGN)](/topic/$amgn) [AstraZeneca PLC (AZN)](/topic/$azn) [Blueprint Medicines Corporation (BPMC)](/topic/$bpmc) [Synthetify (SNY)](/topic/$sny) [Incyte Corporation (INCY)](/topic/$incy) [Santiment Network Token (SAN)](/topic/$san)
### Top Social Posts [#](/creator/twitter::43475268/posts)
---
Top posts by engagements in the last XX hours

"$NVS $ECYT Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer Interesting PFS curves"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1359958953510252546) 2021-02-11 20:14:15 UTC 19.6K followers, XX engagements


"I only recall one other time where there was a run up like this without a media leak. $GSK bid for $EIDX but it had to go through $BBIO so some potential for a leak. In the case of $XLRN wonder what the scenario is"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1441484120144715778) 2021-09-24 19:26:10 UTC 19.6K followers, XX engagements


"This seems like a steal considering $MRK paid lanova close to 600M in in November XX for the pd-1/vegf and 2.7B bio bucks remaining. Though thats only if one thinks there's a very good chance of achieving even 1/3 of the biobucks"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1945155481317646830) 2025-07-15 16:16:20 UTC 19.6K followers, 4578 engagements


"$SRPT gets a platform tech designation on 6/4 for its AAVrh74 viral vector for LGMD 2E/R4 which seems to indicate the viral vector is "well understood" and "utilized by more than one drug without an adverse effect on quality manufacturing or safety". A little more than a month later FDA asks to voluntarily stop all shipments and issues a statement saying Sarepta "refused" the request and also pulls the platform designation just handed a month earlier. A lot of fingers being pointed at SRPT (rightfully)for being far from transparant but the FDA is not without fault either with its new found"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1946508655873995232) 2025-07-19 09:53:22 UTC 19.6K followers, 30K engagements


"$ECYT history with $NVS : NVS X weeks after ECYT signed the PSMA compound - We want to know more about PSMA617. X months later - We may want to buy your company. initial offer - XXXXX then XX then XX then on june 4th NVS to ECYT - hold on. we need to slow down"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1063398044824203265) 2018-11-16 11:47:05 UTC 19.6K followers, XX engagements


"Interesting comment since $GSK has been mainly spending on late oncology drugs like $TSRO. And most of their other deals have been less extravagant than say $GILD $MRK $BMY. Quite difficult to restart an oncology pipeline after predecessor sells off most of it"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1406935087938146305) 2021-06-21 11:20:39 UTC 19.6K followers, XX engagements


"$SMMT also raising 500M through an offering and another 520M through a note which Mr Duggan seems to be mostly funding. Burning through the $PCYC proceeds with $AKAO and now SMMT. For a PD-1/VEGF compound with mainly combo data"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1600108445750788097) 2022-12-06 12:42:36 UTC 19.6K followers, XX engagements


"$MDGL 1st treatment against MASH in EU . Conditional approval dependent on 2nd trial"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1936005209341542823) 2025-06-20 10:16:25 UTC 19.6K followers, 7521 engagements


"Mail on some $GSK deal rumors Both seem like partnerships vs buyouts but unclear how authentic the information is $EIDX $PRTA $BBIO"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1340593908565372928) 2020-12-20 09:44:29 UTC 19.6K followers, XX engagements


"Probably a few exceptions like $TSRO $SRRA where smaller biotechs have made a very good ROI on oncology discards from larger biotechs/pharma but seem to be more examples like $VINC $PBYI $CLVS where that strategy has failed miserably"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1783812752626049070) 2024-04-26 10:57:56 UTC 19.6K followers, 3930 engagements


"Competitor bashing is quite frequent. Just a few years ago it was $ISEE and $APLS. Even between small and big like $MRTX and $AMGN and $CLVS $AZN (which didnt end well for the former). $BPMC has been involved in quite a few with $LOXO then $DCPH and now $COGT. I think they both have valid arguments. Ayvakit went from XXX /300 QD for AdvSM and GIST to 25mg to avoid the intracranial AE's. Remains to be seen how Bezu LT safety holds up though efficacy looks much better. Ava's 1st to market should help and even if Bezu struggles in ISM there is the GIST opportunity so not much to be bearish at a"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1936003314061074602) 2025-06-20 10:08:53 UTC 19.6K followers, 8196 engagements


"$IRWD buying $VECT for 1B . GLP-2 for SBS-IF"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1660601106483773441) 2023-05-22 10:58:50 UTC 19.6K followers, 14.5K engagements


"Interestingly $EIDX started climbing rapidly well above what $BBIO offered around 11/15 when "company C" initially informed mgmt about a substantial offer. Remarkable"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1337422209002954753) 2020-12-11 15:41:17 UTC 19.6K followers, XX engagements


"$INCY could be Party B from the $KDMN bidding process"  
![@bio_clouseau Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::43475268.png) [@bio_clouseau](/creator/x/bio_clouseau) on [X](/post/tweet/1442436008528674824) 2021-09-27 10:28:38 UTC 19.6K followers, XX engagements